Compare AbbVie Inc (ABBV) vs iShares Core MSCI Emerging Markets ETF (IEMG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs iShares Core MSCI Emerging Markets ETF — how do they compare? AbbVie Inc trades at $252.67 (market cap $449.91B), while iShares Core MSCI Emerging Markets ETF trades at $80.05. The key difference: AbbVie Inc pays a 2.72% dividend while iShares Core MSCI Emerging Markets ETF pays none, and AbbVie Inc is trading nearer its 52-week high, iShares Core MSCI Emerging Markets ETF nearer its low. Which is the better fit depends on your goals.
| ABBV | IEMG | |
|---|---|---|
Market Cap | $449.91B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $261.07 | $86.00 |
52-Week Low | $184.85 | $59.90 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.61, down 0.84% on the day, with a bullish technical outlook supported by moving averages and strong support at $248. The company reported revenue of $61.16B in 2025, with EPS beats in recent quarters, though net income margin has trended down to 5.79%. Key growth drivers Skyrizi and Rinvoq are offsetting Humira declines, with positive clinical updates like the Phase 2 ELAHERE data at SGO 2026.
The stock offers a compelling buy case with a consensus price target of $266.33 (5.4% upside) and strong analyst support (68% buy ratings). However, risks include patent cliffs in the 2030s, high debt levels, and margin pressure. Dividend growth is recovering, supporting income investors, but execution on pipeline assets remains critical for sustained expansion.
IEMG trades at $82.00, up 2.71% with strong bullish technical signals from moving averages. The ETF has delivered exceptional performance, surging 35% over the past year according to Fool - Investing News (2026-07-06), driven by its 40% technology weighting and exposure to emerging market growth. Recent news highlights IEMG's valuation discount to US equities and its focus on AI through South Korean and Taiwanese semiconductor stocks.
The outlook remains positive given emerging market growth potential and AI exposure, though risks include elevated volatility at 37% and concentration in tech stocks. Analyst sentiment is mixed with some recommending profit-taking after the strong rally, while others emphasize the long-term growth opportunity in undervalued emerging markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About iShares Core MSCI Emerging Markets ETF
IEMG tracks the MSCI Emerging Markets Investable Market Index, providing broad exposure to large, mid, and small-cap stocks across over 20 emerging market countries. It is designed as a low-cost core holding for investors seeking diversified growth from economies outside of developed markets.
Read more on IEMG →
